Key points from article :
ProMIS Neurosciences, an antibody therapeutics company, has closed a $20.4M private investment in public equity (PIPE) financing round.
The company develops antibody therapeutics that specifically target toxic misfolded proteins associated with neurodegenerative diseases.
ProMIS uses computational algorithms to identify disease-specific targets, minimizing the risk of cross-reactivity.
Proceeds from the PIPE financing will be used to advance the clinical development of PMN310, a lead candidate targeting toxic amyloid-beta oligomers in Alzheimer's.
ProMIS presented preclinical data supporting the potential therapeutic advantage of PMN310 for Alzheimer's in July.
The funding will also support ProMIS' working capital needs and general corporate expenses.
